BFRIW
Biofrontera Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.02
−2.91%Next report
Analyst consensus
- Next report date
- Nov 18, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- $8.3M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.10
- Revenue actual
- $12.0M
- Revenue estimate
- $9.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -16.1%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.10 | -$0.05 | Beat 52.38% | $12.0M |
| May 14, 2026 | -$0.12 | -$0.41 | Miss -256.52% | $10.1M |
| Mar 19, 2026 | $0.20 | $0.48 | Beat 146.15% | $17.1M |
| Nov 12, 2025 | -$0.58 | -$0.62 | Miss -6.38% | $7.0M |
| Aug 13, 2025 | -$0.42 | -$0.57 | Miss -35.55% | $9.0M |
| May 15, 2025 | -$0.21 | -$0.47 | Miss -120.29% | $8.6M |
| Sep 29, 2023 | — | -$0.00 | — | $8.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 18, 2026